Literature DB >> 27634555

The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease.

Aris A Polyzos1, Cynthia T McMurray2.   

Abstract

Mitochondrial dysfunction and ensuing oxidative damage is typically thought to be a primary cause of Huntington's disease, Alzheimer's disease, and Parkinson disease. There is little doubt that mitochondria (MT) become defective as neurons die, yet whether MT defects are the primary cause or a detrimental consequence of toxicity remains unanswered. Oxygen consumption rate (OCR) and glycolysis provide sensitive and informative measures of the functional status MT and the cells metabolic regulation, yet these measures differ depending on the sample source; species, tissue type, age at measurement, and whether MT are measured in purified form or in a cell. The effects of these various parameters are difficult to quantify and not fully understood, but clearly have an impact on interpreting the bioenergetics of MT or their failure in disease states. A major goal of the review is to discuss issues and coalesce detailed information into a reference table to help in assessing mitochondrial dysfunction as a cause or consequence of Huntington's disease. Published by Elsevier B.V.

Entities:  

Keywords:  Electron transport chain; Huntington’s disease; Metabolism; Mitochondria; Neurodegenerative disease

Mesh:

Year:  2016        PMID: 27634555      PMCID: PMC5543717          DOI: 10.1016/j.mad.2016.09.003

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  120 in total

1.  Threshold effect and tissue specificity. Implication for mitochondrial cytopathies.

Authors:  R Rossignol; M Malgat; J P Mazat; T Letellier
Journal:  J Biol Chem       Date:  1999-11-19       Impact factor: 5.157

2.  Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production.

Authors:  P Guidetti; V Charles; E Y Chen; P H Reddy; J H Kordower; W O Whetsell; R Schwarcz; D A Tagle
Journal:  Exp Neurol       Date:  2001-06       Impact factor: 5.330

3.  Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse.

Authors:  S J Tabrizi; J Workman; P E Hart; L Mangiarini; A Mahal; G Bates; J M Cooper; A H Schapira
Journal:  Ann Neurol       Date:  2000-01       Impact factor: 10.422

4.  Neurological abnormalities in a knock-in mouse model of Huntington's disease.

Authors:  C H Lin; S Tallaksen-Greene; W M Chien; J A Cearley; W S Jackson; A B Crouse; S Ren; X J Li; R L Albin; P J Detloff
Journal:  Hum Mol Genet       Date:  2001-01-15       Impact factor: 6.150

5.  Transgenic rat model of Huntington's disease.

Authors:  Stephan von Hörsten; Ina Schmitt; Huu Phuc Nguyen; Carsten Holzmann; Thorsten Schmidt; Thomas Walther; Michael Bader; Reinhard Pabst; Philipp Kobbe; Jana Krotova; Detlef Stiller; Ants Kask; Annika Vaarmann; Silvia Rathke-Hartlieb; Jörg B Schulz; Ute Grasshoff; Ingrid Bauer; Ana Maria Menezes Vieira-Saecker; Martin Paul; Lesley Jones; Katrin S Lindenberg; Bernhard Landwehrmeyer; Andreas Bauer; Xiao-Jiang Li; Olaf Riess
Journal:  Hum Mol Genet       Date:  2003-03-15       Impact factor: 6.150

6.  Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy.

Authors:  R Lodi; A H Schapira; D Manners; P Styles; N W Wood; D J Taylor; T T Warner
Journal:  Ann Neurol       Date:  2000-07       Impact factor: 10.422

7.  A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.

Authors:  J G Hodgson; N Agopyan; C A Gutekunst; B R Leavitt; F LePiane; R Singaraja; D J Smith; N Bissada; K McCutcheon; J Nasir; L Jamot; X J Li; M E Stevens; E Rosemond; J C Roder; A G Phillips; E M Rubin; S M Hersch; M R Hayden
Journal:  Neuron       Date:  1999-05       Impact factor: 17.173

8.  Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice.

Authors:  Silvia Gines; Ihn Sik Seong; Elisa Fossale; Elena Ivanova; Flavia Trettel; James F Gusella; Vanessa C Wheeler; Francesca Persichetti; Marcy E MacDonald
Journal:  Hum Mol Genet       Date:  2003-03-01       Impact factor: 6.150

9.  Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease?

Authors:  L Kennedy; P F Shelbourne
Journal:  Hum Mol Genet       Date:  2000-10-12       Impact factor: 6.150

10.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Authors:  Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

View more
  13 in total

1.  Metabolic Reprogramming in Astrocytes Distinguishes Region-Specific Neuronal Susceptibility in Huntington Mice.

Authors:  Aris A Polyzos; Do Yup Lee; Rupsa Datta; Meghan Hauser; Helen Budworth; Amy Holt; Stephanie Mihalik; Pike Goldschmidt; Ken Frankel; Kelly Trego; Michael J Bennett; Jerry Vockley; Ke Xu; Enrico Gratton; Cynthia T McMurray
Journal:  Cell Metab       Date:  2019-03-28       Impact factor: 27.287

2.  Brain mitochondrial iron accumulates in Huntington's disease, mediates mitochondrial dysfunction, and can be removed pharmacologically.

Authors:  Sonal Agrawal; Julia Fox; Baskaran Thyagarajan; Jonathan H Fox
Journal:  Free Radic Biol Med       Date:  2018-04-04       Impact factor: 7.376

3.  Oxidative metabolism and Ca2+ handling in striatal mitochondria from YAC128 mice, a model of Huntington's disease.

Authors:  James Hamilton; Tatiana Brustovetsky; Nickolay Brustovetsky
Journal:  Neurochem Int       Date:  2017-01-03       Impact factor: 3.921

4.  Energy Metabolism and Mitochondrial Superoxide Anion Production in Pre-symptomatic Striatal Neurons Derived from Human-Induced Pluripotent Stem Cells Expressing Mutant Huntingtin.

Authors:  James Hamilton; Tatiana Brustovetsky; Akshayalakshmi Sridhar; Yanling Pan; Theodore R Cummins; Jason S Meyer; Nickolay Brustovetsky
Journal:  Mol Neurobiol       Date:  2019-08-21       Impact factor: 5.590

5.  Impaired response of cerebral oxygen metabolism to visual stimulation in Huntington's disease.

Authors:  Peter Klinkmueller; Martin Kronenbuerger; Xinyuan Miao; Jee Bang; Kia E Ultz; Adrian Paez; Xiaoyu Zhang; Wenzhen Duan; Russell L Margolis; Peter Cm van Zijl; Christopher A Ross; Jun Hua
Journal:  J Cereb Blood Flow Metab       Date:  2020-08-17       Impact factor: 6.200

6.  Comparison of Sirtuin 3 Levels in ALS and Huntington's Disease-Differential Effects in Human Tissue Samples vs. Transgenic Mouse Models.

Authors:  Eva Buck; Hanna Bayer; Katrin S Lindenberg; Johannes Hanselmann; Noemi Pasquarelli; Albert C Ludolph; Patrick Weydt; Anke Witting
Journal:  Front Mol Neurosci       Date:  2017-05-26       Impact factor: 5.639

Review 7.  Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases.

Authors:  Niamh M C Connolly; Pierre Theurey; Vera Adam-Vizi; Nicolas G Bazan; Paolo Bernardi; Juan P Bolaños; Carsten Culmsee; Valina L Dawson; Mohanish Deshmukh; Michael R Duchen; Heiko Düssmann; Gary Fiskum; Maria F Galindo; Giles E Hardingham; J Marie Hardwick; Mika B Jekabsons; Elizabeth A Jonas; Joaquin Jordán; Stuart A Lipton; Giovanni Manfredi; Mark P Mattson; BethAnn McLaughlin; Axel Methner; Anne N Murphy; Michael P Murphy; David G Nicholls; Brian M Polster; Tullio Pozzan; Rosario Rizzuto; Jorgina Satrústegui; Ruth S Slack; Raymond A Swanson; Russell H Swerdlow; Yvonne Will; Zheng Ying; Alvin Joselin; Anna Gioran; Catarina Moreira Pinho; Orla Watters; Manuela Salvucci; Irene Llorente-Folch; David S Park; Daniele Bano; Maria Ankarcrona; Paola Pizzo; Jochen H M Prehn
Journal:  Cell Death Differ       Date:  2017-12-11       Impact factor: 15.828

8.  Bioenergetic deficits in Huntington's disease iPSC-derived neural cells and rescue with glycolytic metabolites.

Authors: 
Journal:  Hum Mol Genet       Date:  2020-07-21       Impact factor: 6.150

9.  Accelerated expansion of pathogenic mitochondrial DNA heteroplasmies in Huntington's disease.

Authors:  Yiqin Wang; Xiaoxian Guo; Kaixiong Ye; Michael Orth; Zhenglong Gu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-27       Impact factor: 11.205

10.  Expression of mutant exon 1 huntingtin fragments in human neural stem cells and neurons causes inclusion formation and mitochondrial dysfunction.

Authors:  Rhia Ghosh; Alison Wood-Kaczmar; Lucianne Dobson; Edward J Smith; Eva C Sirinathsinghji; Janos Kriston-Vizi; Iain P Hargreaves; Robert Heaton; Frank Herrmann; Andrey Y Abramov; Amanda J Lam; Simon J Heales; Robin Ketteler; Gillian P Bates; Ralph Andre; Sarah J Tabrizi
Journal:  FASEB J       Date:  2020-04-23       Impact factor: 5.834

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.